Symbols / ENTX Stock $1.30 -5.11% Entera Bio Ltd.

Healthcare • Biotechnology • Israel • NCM
ENTX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Ms. Miranda J. Toledano M.B.A.
Exch · Country NCM · Israel
Market Cap 70.79M
Enterprise Value 53.99M
Income -11.44M
Sales 42.00K
FCF (ttm) -11.44M
Book/sh 0.28
Cash/sh 0.15
Employees 20
Insider 10d —
IPO Jun 28, 2018
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -2.36
PEG —
P/S 1,685.36
P/B 4.58
P/C —
EV/EBITDA -4.70
EV/Sales 1,285.50
Quick Ratio 3.33
Current Ratio 6.94
Debt/Eq 3.74
LT Debt/Eq —
EPS (ttm) -0.25
EPS next Y -0.55
EPS Growth —
Revenue Growth -100.00%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-08
Earnings (prior) 2026-05-08
ROA -56.78%
ROE -108.01%
ROIC —
Gross Margin 0.00%
Oper. Margin -274.50%
Profit Margin 0.00%
Shs Outstand 54.45M
Shs Float 32.24M
Insider Own 20.94%
Instit Own 17.11%
Short Float 0.40%
Short Ratio 1.08
Short Interest 192.78K
52W High 3.22
vs 52W High -59.63%
52W Low 0.91
vs 52W Low 42.86%
Beta 1.55
Impl. Vol. 25.00%
Rel Volume 0.71
Avg Volume 174.08K
Volume 123.98K
Target (mean) $9.00
Tgt Median $9.00
Tgt Low $9.00
Tgt High $9.00
# Analysts 1
Recom Strong_buy
Prev Close $1.37
Price $1.30
Change -5.11%
About

Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist peptide, which is in Phase I clinical trial for the treatment of obesity, metabolic, and fibrotic disorders; and GLP-2 which is in Phase I clinical trial for the treatment of short bowel syndrome and disorders related to mucosal inflammation and nutrient malabsorption. It has a collaboration agreement with OPKO Biologics, Inc for the preclinical and clinical development of LA-PTH and oral dual agonist GLP-1/glucagon peptide. The company was incorporated in 2009 and is based in Jerusalem, Israel.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$9.00
Mean price target
2. Current target
$1.30
Latest analyst target
3. DCF / Fair value
$-3.78
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.30
Low
$9.00
High
$9.00
Mean
$9.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-27 main HC Wainwright & Co. Buy → Buy $9
2026-02-09 reit HC Wainwright & Co. Buy → Buy $10
2025-03-18 reit HC Wainwright & Co. Buy → Buy $10
2024-11-11 reit HC Wainwright & Co. Buy → Buy $10
2024-10-07 reit HC Wainwright & Co. Buy → Buy $10
2024-09-27 reit HC Wainwright & Co. Buy → Buy $10
2024-08-12 reit HC Wainwright & Co. Buy → Buy $10
2024-06-05 reit HC Wainwright & Co. Buy → Buy $10
2024-05-14 reit HC Wainwright & Co. Buy → Buy $10
2024-05-13 reit HC Wainwright & Co. Buy → Buy $10
2024-04-02 main HC Wainwright & Co. Buy → Buy $10
2023-12-11 reit HC Wainwright & Co. Buy → Buy $10
2023-09-13 reit HC Wainwright & Co. Buy → Buy $10
2023-09-11 reit HC Wainwright & Co. Buy → Buy $10
2023-05-08 reit HC Wainwright & Co. — → Buy $10
2023-04-04 reit HC Wainwright & Co. — → Buy $10
2023-03-28 reit HC Wainwright & Co. — → Buy $10
2022-09-06 init HC Wainwright & Co. — → Buy $10
2022-07-19 main B. Riley Securities — → Buy $5
2021-06-16 init B. Riley Securities — → Buy $9
News
RSS: Latest ENTX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-09 GERMANO GENO J Director — 20,000 $1.30 $26,000
2026-03-05 ELLIS SEAN Director — 10,000 $1.23 $12,300
2026-02-12 RUBIN STEVEN DANIEL Director — 5,000 $1.49 $7,450
2026-02-10 GERMANO GENO J Director — 20,000 $1.49 $29,800
2026-02-10 TAITEL HAYA Director — 7,500 $1.48 $11,100
2026-02-09 RUBIN STEVEN DANIEL Director — 10,000 $1.20 $12,000
2026-02-09 ELLIS SEAN Director — 18,000 $1.24 $22,320
2025-12-31 LIEBERMAN GERALD M Director — 38,294 $0.00 $0
2025-12-31 OSTROV GERALD M Director — 28,721 $0.00 $0
2025-12-31 ELLIS SEAN Director — 25,371 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.04
-76.80%
0.18
0.00
-100.00%
0.13
Operating Revenue
0.04
-76.80%
0.18
0.00
-100.00%
0.13
Cost Of Revenue
0.04
-75.58%
0.17
0.00
-100.00%
0.10
Reconciled Cost Of Revenue
0.04
-75.58%
0.17
0.00
-100.00%
0.10
Gross Profit
0.00
-100.00%
0.01
0.00
-100.00%
0.03
Operating Expense
11.53
+20.17%
9.59
+7.91%
8.89
-31.87%
13.05
Research And Development
6.00
+33.45%
4.50
-0.24%
4.51
-22.88%
5.85
Selling General And Administration
5.53
+8.44%
5.09
+15.01%
4.43
-38.92%
7.25
General And Administrative Expense
5.53
+8.44%
5.09
+15.01%
4.43
-38.92%
7.25
Other Gand A
5.53
+8.44%
5.09
+15.01%
4.43
-38.92%
7.25
Other Operating Expenses
—
—
-0.05
+3.92%
-0.05
Total Expenses
11.57
+18.48%
9.77
+9.84%
8.89
-32.39%
13.15
Operating Income
-11.53
-20.28%
-9.59
-7.81%
-8.89
+31.70%
-13.02
Total Operating Income As Reported
-11.53
-20.28%
-9.59
-7.81%
-8.89
+31.70%
-13.02
EBITDA
-11.50
-20.55%
-9.54
-7.97%
-8.84
+31.79%
-12.95
Normalized EBITDA
-11.50
-20.55%
-9.54
-7.97%
-8.84
+31.79%
-12.95
Reconciled Depreciation
0.03
-34.78%
0.05
-17.86%
0.06
-12.50%
0.06
EBIT
-11.53
-20.28%
-9.59
-7.81%
-8.89
+31.70%
-13.02
Net Income
-11.44
-19.89%
-9.54
-7.33%
-8.89
+31.99%
-13.07
Pretax Income
-11.44
-20.07%
-9.53
-7.53%
-8.86
+31.50%
-12.93
Net Non Operating Interest Income Expense
0.09
+55.17%
0.06
+87.10%
0.03
-62.65%
0.08
Interest Expense Non Operating
—
—
—
—
Net Interest Income
0.09
+55.17%
0.06
+87.10%
0.03
-62.65%
0.08
Interest Expense
—
—
—
—
Tax Provision
0.00
-100.00%
0.01
-51.72%
0.03
-78.83%
0.14
Tax Rate For Calcs
0.00
-100.00%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-11.44
-19.89%
-9.54
-7.33%
-8.89
+31.99%
-13.07
Net Income From Continuing Operation Net Minority Interest
-11.44
-19.89%
-9.54
-7.33%
-8.89
+31.99%
-13.07
Net Income From Continuing And Discontinued Operation
-11.44
-19.89%
-9.54
-7.33%
-8.89
+31.99%
-13.07
Net Income Continuous Operations
-11.44
-19.89%
-9.54
-7.33%
-8.89
+31.99%
-13.07
Normalized Income
-11.44
-19.89%
-9.54
-7.33%
-8.89
+31.99%
-13.07
Net Income Common Stockholders
-11.44
-19.89%
-9.54
-7.33%
-8.89
+31.99%
-13.07
Diluted EPS
-0.25
+0.00%
-0.25
+19.35%
-0.31
+31.11%
-0.45
Basic EPS
-0.25
+0.00%
-0.25
+19.35%
-0.31
+31.11%
-0.45
Basic Average Shares
46.19
+22.68%
37.65
+29.79%
29.01
+0.69%
28.81
Diluted Average Shares
46.19
+22.68%
37.65
+29.79%
29.01
+0.69%
28.81
Diluted NI Availto Com Stockholders
-11.44
-19.89%
-9.54
-7.33%
-8.89
+31.99%
-13.07
Total Other Finance Cost
-0.09
-55.17%
-0.06
-87.10%
-0.03
+62.65%
-0.08
Line Item Trend 2023-12-31
Total Assets
11.77
Current Assets
11.26
Cash Cash Equivalents And Short Term Investments
11.02
Cash And Cash Equivalents
11.02
Receivables
0.00
Accounts Receivable
0.00
Restricted Cash
—
Other Current Assets
0.24
Total Non Current Assets
0.51
Net PPE
0.49
Gross PPE
0.49
Other Properties
0.49
Non Current Deferred Assets
0.01
Non Current Deferred Taxes Assets
0.01
Other Non Current Assets
—
Total Liabilities Net Minority Interest
1.38
Current Liabilities
1.09
Payables And Accrued Expenses
0.58
Payables
0.08
Accounts Payable
0.08
Other Payable
—
Current Accrued Expenses
0.50
Employee Benefits
0.03
Pensionand Other Post Retirement Benefit Plans Current
0.37
Total Tax Payable
—
Income Tax Payable
—
Current Debt And Capital Lease Obligation
0.13
Current Capital Lease Obligation
0.13
Current Deferred Liabilities
—
Current Deferred Revenue
—
Total Non Current Liabilities Net Minority Interest
0.29
Long Term Debt And Capital Lease Obligation
0.26
Long Term Capital Lease Obligation
0.26
Defined Pension Benefit
0.01
Non Current Pension And Other Postretirement Benefit Plans
0.03
Other Non Current Liabilities
—
Stockholders Equity
10.39
Common Stock Equity
10.39
Capital Stock
0.00
Common Stock
0.00
Share Issued
35.48
Ordinary Shares Number
35.48
Treasury Shares Number
0.00
Additional Paid In Capital
114.73
Retained Earnings
-104.39
Gains Losses Not Affecting Retained Earnings
0.04
Other Equity Adjustments
0.04
Total Equity Gross Minority Interest
10.39
Total Capitalization
10.39
Working Capital
10.17
Invested Capital
10.39
Total Debt
0.39
Capital Lease Obligations
0.39
Net Tangible Assets
10.39
Tangible Book Value
10.39
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-7.37
-8.10%
-6.82
+6.73%
-7.31
+41.52%
-12.50
Cash Flow From Continuing Operating Activities
-7.37
-8.10%
-6.82
+6.73%
-7.31
+41.52%
-12.50
Net Income From Continuing Operations
-11.44
-19.89%
-9.54
-7.33%
-8.89
+31.99%
-13.07
Depreciation Amortization Depletion
0.03
-34.78%
0.05
-17.86%
0.06
-12.50%
0.06
Depreciation
0.03
-34.78%
0.05
-17.86%
0.06
-12.50%
0.06
Depreciation And Amortization
0.03
-34.78%
0.05
-17.86%
0.06
-12.50%
0.06
Other Non Cash Items
0.03
+740.00%
-0.01
—
-0.08
Stock Based Compensation
2.75
+7.59%
2.56
+51.33%
1.69
-24.83%
2.25
Deferred Tax
—
0.01
-51.72%
0.03
-83.33%
0.17
Deferred Income Tax
—
0.01
-51.72%
0.03
-83.33%
0.17
Change In Working Capital
1.26
+1022.32%
0.11
+157.44%
-0.20
+89.37%
-1.83
Change In Receivables
0.13
+200.00%
-0.13
-151.22%
0.25
+490.48%
-0.06
Changes In Account Receivables
0.13
+200.00%
-0.13
-151.22%
0.25
+490.48%
-0.06
Change In Payables And Accrued Expense
1.36
+439.68%
0.25
+150.70%
-0.50
+71.05%
-1.72
Change In Accrued Expense
1.04
+414.29%
0.20
+136.06%
-0.56
+64.09%
-1.57
Change In Payable
0.32
+544.90%
0.05
-25.76%
0.07
+144.30%
-0.15
Change In Account Payable
0.32
+544.90%
0.05
-25.76%
0.07
+144.30%
-0.15
Change In Other Working Capital
—
—
—
-0.01
Change In Other Current Assets
-0.23
-1535.71%
-0.01
-125.00%
0.06
+240.00%
-0.04
Investing Cash Flow
-0.11
-3466.67%
-0.00
+82.35%
-0.02
+83.33%
-0.10
Cash Flow From Continuing Investing Activities
-0.11
-3466.67%
-0.00
+82.35%
-0.02
+83.33%
-0.10
Net PPE Purchase And Sale
-0.11
-3466.67%
-0.00
+82.35%
-0.02
+63.83%
-0.05
Purchase Of PPE
-0.11
-3466.67%
-0.00
+82.35%
-0.02
+63.83%
-0.05
Capital Expenditure
-0.11
-3466.67%
-0.00
+82.35%
-0.02
+63.83%
-0.05
Net Other Investing Changes
—
—
—
-0.06
Financing Cash Flow
13.71
+206.30%
4.48
-25.84%
6.04
+46330.77%
0.01
Cash Flow From Continuing Financing Activities
13.71
+206.30%
4.48
-25.84%
6.04
+46330.77%
0.01
Net Common Stock Issuance
13.44
+239.49%
3.96
-40.15%
6.62
0.00
Proceeds From Stock Option Exercised
0.53
-37.07%
0.84
0.00
-100.00%
0.01
Net Other Financing Charges
-0.26
+18.89%
-0.32
+44.31%
-0.58
—
Changes In Cash
6.27
+367.33%
-2.35
-81.64%
-1.29
+89.74%
-12.59
Effect Of Exchange Rate Changes
-0.04
0.00
—
—
Beginning Cash Position
8.74
-21.15%
11.09
-10.43%
12.38
-50.42%
24.96
End Cash Position
14.97
+71.32%
8.74
-21.15%
11.09
-10.43%
12.38
Free Cash Flow
-7.48
-9.62%
-6.82
+6.91%
-7.33
+41.60%
-12.55
Income Tax Paid Supplemental Data
—
—
0.00
-100.00%
0.17
Common Stock Issuance
13.44
+239.49%
3.96
-40.15%
6.62
0.00
Issuance Of Capital Stock
13.44
+239.49%
3.96
-40.15%
6.62
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category